Adlai Nortye Ltd.
ANL evidence brief
What we can confirm
- Market Cap:
- $1.03B
What it means
What to watch
Prepared research question
What matters most for ANL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANL
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology company developing innovative cancer therapies, with a focus on pan-RAS inhibitors and other oncology assets.
Key risk: No approved products
Market Cap
$1.03B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2024.
Tracking 7 clinical trials for Adlai Nortye Ltd..
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology company developing innovative cancer therapies, with a focus on pan-RAS inhibitors and other oncology assets.
- Cash & equivalents of $60.9M as of 2024-12-31 [sec].
- Enrollment ongoing in global Phase I trial of pan-RAS(ON) inhibitor AN9025 as of August 2026 [news].
- First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 as of August 2026 [news].
- Exclusive license agreement with ASK Pharm for AN9025 in Greater China announced December 2025 [news].
- Two leading medical oncologists appointed to Scientific Advisory Board as of August 2026 [news].
What works
- Ongoing global Phase I trial for pan-RAS(ON) inhibitor AN9025, a potentially novel approach in oncology [news].
- First regulatory approval for Phase I trial of pan-RAS(ON) ADC AN4035, expanding pipeline into antibody-drug conjugates [news].
- Exclusive licensing agreement with ASK Pharm for AN9025 in Greater China provides regional partnership and potential revenue [news].
- Appointment of two leading medical oncologists to Scientific Advisory Board strengthens clinical expertise [news].
What to weigh
- Company is clinical-stage with no approved products, implying no current revenue from product sales [news].
- Cash & equivalents of $60.9M as of 2024-12-31 may be limited for multiple ongoing trials and operations [sec].
- Competitive landscape includes numerous companies developing advanced solid tumor therapies, such as Nanjing Leads Biolabs and Novartis [competitor_trial].
- Stock price volatility noted with a ~1,600% surge since Dec. 2025, suggesting high risk for investors [news].
From the filings
Quoted directly from source documents.
Phase I trial enrollment for AN9025
“Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025”
News · August 14, 2026
Regulatory approval for AN4035 Phase I trial
“First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035”
News · August 14, 2026
License agreement with ASK Pharm
“Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China”
News · December 29, 2025
Catalyst timeline
- 2020-12-12 · Phase3_Start: The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Phase 3 trial start for AN2025; watch for efficacy and safety data updates.
- 2021-09-07 · Phase1_Start: An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination With Atezolizumab and in Triple Combination With Atezolizumab in Patients With Advanced Solid Tumors — Phase 1a study start for combination therapies; monitor for early clinical signals.
- 2021-09-27 · Phase1_Start: Clinical Study Protocol AN4005X0101 An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients With Advanced Tumors — Phase 1 study start for AN4005; watch for safety and pharmacokinetic data.
- 2025-11-01 · Phase1_Start: Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of AN8025 in Participants With Unresectable — Phase 1 study start for AN8025; monitor for initial results on safety and activity.
Risks & what to watch (4)›
Key risks
- No approved products — Company is clinical-stage with no marketed drugs, relying on trial outcomes for future revenue [news].
- Limited cash runway — Cash & equivalents of $60.9M as of 2024-12-31 may be insufficient for multiple trials [sec].
- Intense competition — Multiple competitors developing advanced solid tumor therapies, e.g., Nanjing Leads Biolabs [competitor_trial].
- Stock volatility — Stock surged ~1,600% since Dec. 2025, indicating high speculative risk [news].
What to watch
- Progress and results from the global Phase I trial of AN9025 [news].
- Initiation and early data from the Phase I trial of AN4035 [news].
- Potential milestones from the ASK Pharm partnership for AN9025 in Greater China [news].
- Any updates on cash position and financial runway from future financial reports [sec].
Sources: Catalysts · Competitor trials · News · Generated October 13, 2026 · How we verify sources →
Run Adlai Nortye Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Adlai Nortye Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 1, 2026- % of float
- 4.9%
- Days to cover
- 5.3
- Shares short
- 2,294,430
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANL short interestFrequently asked questions
What is the AI investment thesis for Adlai Nortye Ltd.?
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology company developing innovative cancer therapies, with a focus on pan-RAS inhibitors and other oncology assets.
Who is the CEO of Adlai Nortye Ltd.?
Mr. Yang Lu EMBA is the chief executive officer of Adlai Nortye Ltd. (ANL).
Where is Adlai Nortye Ltd. headquartered?
Adlai Nortye Ltd. (ANL) is headquartered in Singapore, Singapore.
What therapeutic areas does Adlai Nortye Ltd. focus on?
Adlai Nortye Ltd. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.